pharmaceutical-investing InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901
pharmaceuticals-investing InMed Pharmaceuticals: Innovating Cannabinoid-inspired Medicines, Backed by Real Revenue and Clear Path to Value
InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules
FDA Accepts LEQEMBI® IQLIK Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
FDA Accepts LEQEMBI® IQLIKTM Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review
Data at 2026 Boswick Burn & Wound Symposium highlight first integrated use of AVITA Medical technologies
CORRECTION - Domestic Metals Engages ICP Securities Inc. for Automated Market Making Services and provides further details on the engagement of Michael Pound
